CST: 23/08/2016 21:31:26   

OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in Europe

160 Days ago

BATON ROUGE, LA --(Marketwired - March 16, 2016) - OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notice of Allowance for a patent on ProscaVax™, OncBioMune's cancer vaccine in a Phase 1 trial for relapsed prostate cancer patients, from the European Patent Office.

The patent, titled "Composition and Method for Treating Cancer," application number 12701292.0, expands the scope of protection of OncBioMune's intellectual property, which now includes 15 patents and patents pending covering approximately 50 countries worldwide for the Company's vaccine and paclitaxel gallium transferrin (PGT) technologies.

ProscaVax is a novel protein therapeutic cancer vaccine combining tumor-associated antigens with biological adjuvants to selectively target tumor cells without damaging healthy cells. OncBioMune recently disclosed that while the Phase 1 trial is completed, a Phase 2 trial is expected to be initiated later this year evaluating ProscaVax as a front-line treatment for prostate cancer patients at disease presentation.

According to Cancer Research UK, approximately 417,000 men were diagnosed with prostate cancer in Europe in 2012 and more than 92,000 men died from the disease. 

"As we explore all developmental avenues globally for ProscaVax, protecting our intellectual property is critical," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "Prostate cancer is the most common cancer in Europe for men and the third most common cancer overall. We hope that one day ProscaVax will provide a viable solution in the region to meet this area of great unmet medical need."

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

INVESTOR AND MEDIA CONTACT:
OncBioMune Pharmaceuticals, Inc.
Andrew Kucharchuk
President and Chief Financial Officer
akucharchuk@oncbiomune.com